Inclusion Criteria:  Patient with diagnosis of primary liver tumor or metastases in the liver. Patients treated with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres from 15 July 2019 to 15 July 2021. Patient is ≥ 18 years. If required by national regulation, patient has understood and signed written informed consent to retrospective data collection.  Exclusion Criteria:  Patients previously included in prospective interventional study with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres.